Abstract
Cervical giant cell tumor of the bone (GCTB) is a rare, primary benign bone tumor in pediatric patients. Surgery remains the primary choice for treating resectable cervical GCTB. Additional adjuvant therapeutic options are available for patients with unresectable cervical GCTB, including the anti-RANKL monoclonal antibody, denosumab. We represented a case incidentally found in a 7-year-old female, who complained severe craniocervical pain, grade 2–3 dysphagia, dysphonia, hypesthesia, and extremity weakness. The patient showed an impressive clinical response to denosumab, both clinically and radiologically, without adverse events or recurrence. To date, this is the youngest patient ever reported to have a progressive Enneking stage II C3 GCTB treated with denosumab alone. Denosumab can be administered as a single and conservative therapy for pediatric patients with unresectable upper cervical GCTB, avoiding the risks and morbidity of surgical and radiative treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data and materials supporting our findings can be found in the Department of Orthopedics, Shanghai Changzhen Hospital and Department of Orthopedics, 72nd Group Military Hospital. All the authors wish to share their data. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Change history
14 May 2024
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1007/s10142-024-01371-6
Abbreviations
- GCTB:
-
Cervical giant cell tumor of the bone
- CT:
-
Computed tomography
- MRI:
-
Magnetic resonance imaging
References
Chang YC, Stoyanova R, Danilova S, Pretell-Mazzini JA, Kerr DA, Wilky BA, Subhawong T (2021) Radiomics on radiography predicts giant cell tumor histologic response to denosumab. Skelet Radiol 50:1881–1887. https://doi.org/10.1007/s00256-021-03752-5
Chatterjee D, Gupta K, Singla N, Kapoor A (2016) Sphenoid bone: a rare site for giant cell tumor – case report with literature review. Clin Neuropathol 35(6):385. https://doi.org/10.5414/NP300970
Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efcacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901–908
Chen G, Li J, Li X, Fan H, Guo Z, Wang Z (2015) Giant cell tumor of axial vertebra: surgical experience of fifive cases and a review of the literature. World J Surg Oncol 13:62
Chen X, Li H, Zhu S, Wang Y, Qian W (2020) Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis. BMC Musculoskelet Disord 21(1):1–9. https://doi.org/10.1186/s12891-020-03294-2
Cleven AH, Hocker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovee JV (2015) Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol 39:1576–1583
Demura S, Kato S, Yoshioka K, Shinmura K, Yokogawa N (2022) The influence of costal resection on pulmonary function after total en bloc spondylectomy for spine tumor. J Orthop. https://doi.org/10.1016/j.jos.2022.07.015
Duan P-G, Sheng Y-H, Deng C-H, Tang B-Y, Yao H-Q (2020) Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report. BMC Musculoskelet Disord 21(1):1–7. https://doi.org/10.1186/s12891-020-3129-4
Goldschlager T, Dea N, Boyd M, Reynolds J, Patel S, Rhines LD et al (2015) Giant cell tumors of the spine: has denosumab changed the treatment paradigm? J Neurosurg Spine 22:526–533
Jia Q, Chen G, Cao J et al (2019) Clinical features and prognostic factors of pediatric spine giant cell tumors: report of 31 clinical cases in a single center. Spine J 19:1232–1241
Lim CY, Liu X, He F, Liang H, Yang Y, Ji T, Guo W (2020) Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy. Bone & Joint J 102(2):177–185. https://doi.org/10.1302/0301-620x.102b2.bjj-2019-0813.r1
Li Z, Guo L, Zhang P, Wang J, Wang X (2022) A systematic review of perioperative complications in en bloc resection for spinal tumors . Global Spine J. https://doi.org/10.1177/21925682221120644
Meng Y, Ma J, Shu L, Zhou X et al (2020) Modified C7 pedicle subtraction osteotomy for the correction of cervicothoracic kyphosis. BMC Musculoskelet Disord 21:28. https://doi.org/10.1186/s12891-020-3053-7
Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR (2021) The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Bone & Joint J 103(1):184–191. https://doi.org/10.1302/0301-620x.103b1.bjj-2020-0274.r1
Tsukamoto S, Mavrogenis AF, Tanaka Y, Kido A, Kawaguchi M, Errani C (2021) Denosumab does not decrease local recurrence in giant cell tumor of bone treated with en bloc resection. Orthopedics 44(6):326–332. https://doi.org/10.3928/01477447-20211001-09
Yang Y, Xu H, Liu W, Niu X (2021a) Study of imaging changes following preoperative denosumab for giant cell tumor of bone. J Bone Oncol 32:100410. https://doi.org/10.1016/j.jbo.2021.100410
Yang Y, Xu H, Liu W (2021b) Study of imaging changes following preoperative denosumab for giant cell tumor of bone. J Bone Oncol. https://doi.org/10.1016/j.jbo.2021.100410
Yue J, Sun W, Li S (2022) Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: a randomized clinical trial. J Bone Oncol 35:100441. https://doi.org/10.1016/j.jbo.2022.100441
Funding
This study was financially supported by grants from the Clinical Research Fund project of Zhejiang Province and Intensive Research of The 98th Hospital of the PLA (No. 2018ZYC-A78) and the Clinical Research Fund project of Huzhou city and Intensive Research of The 98th Hospital of the PLA (No. 2019GYB-32).
Author information
Authors and Affiliations
Contributions
JieFeng Zhang conceived the study, participated in its design and coordination, and helped to draft the manuscript. Treatment was performed by Xiaoming Li and Xuhui Zhou. YiXuan Tan and Jinling Zhang were the major contributors in writing the manuscript. Shuhan Zhang and Tao Huang analyzed the radiographic data. All authors read and approved the final manuscript. All contributors who do not meet the criteria for authorship should be listed in the Acknowledgements section.
Corresponding authors
Ethics declarations
Ethical approval
The Shanghai Changzhen Hospital and the 72nd Army Hospital approved this case report to be published.
Informed consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
YiXuan Tan, Shuhan Zhang, Jinling Zhang and Tao Huang contributed equally to this work as co-first author.
This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1007/s10142-024-01371-6
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tan, Y., Zhang, S., Zhang, J. et al. RETRACTED ARTICLE: Denosumab treatment for progressive Enneking stage II cervical giant-cell tumor conservatively. Funct Integr Genomics 23, 76 (2023). https://doi.org/10.1007/s10142-023-01004-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01004-4